BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies for healthcare professionals in clinical and research settings worldwide.
The last earnings update was 62 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
BioPorto. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
BioPorto's earnings available for a low price, and how does
this compare to other companies in the same industry?
BioPorto's earnings are expected to grow significantly at over 20% yearly.
BioPorto's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
BioPorto's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Peter Mørch Eriksen, BBA, has been a Director at Fluoguide A/s since 2019. He serves as Chief Executive Officer of BioPorto Diagnostics A/S. Mr. Eriksen has been the Chief Executive Officer of BioPorto A/S since July 18,2013. Mr. Eriksen served as an Administration Director of BioPorto A/S. Mr. Eriksen serves as the Chief Executive Officer of Sense A/S. He has more than 15 years of experience within medtech/life science in Denmark and abroad. He served as Vice President of Medtronic in both the USA and Denmark. He has extensive experience in creating growth, restructuring and funding in technology intensive and complex companies. He has an accounting background supplemented with courses in management. He has long experience in selling and developing medical devices for both small and large medtech companies. He is an executive leader with a record of business within the medical device industry. He served as the Chief Executive Officer of Pnn Medical A/S from 2008 to 2009 and Vice President/General Manager of Medtronic Inc. from 1997 to 2004 in the US. He served as the Chief Operating Officer of Maconomy. He served as the Chief Executive Officer/Chief Financial Officer of Brüel & Kjaer. He contributes with to NORMA’s success with his executive skills in establishing international business organizations and strong understanding of the complexities of medical devices and their clinical trials. He serves as the Chairman of MTIC. He serves as a Member of Lund University Advisory Board and Director of PMEconsult. He serves as a Member of the Board at NORMA A/S.
Peter's compensation has been consistent with company performance over the past year.
Peter's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the BioPorto management team is about average.
Chief Executive Officer
Chief Financial Officer
Chief Operation Officer
Chief Scientific Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the BioPorto board of directors is about average.
BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies for healthcare professionals in clinical and research settings worldwide. The company offers the neutrophil gelatinase-associated lipocalin (NGAL) test, a particle-enhanced turbidimetric test that measures NGAL that is used on clinical chemical analyzers; NGAL enzyme-linked immunosorbent assay (ELISA) kits for human use, as well as used in research and clinical practice; and MBL ELISA kit, which is based on MBL antibodies. It also provides monoclonal antibodies that cover various research disciplines, such as microbiology, immune deficiency, renal, peptide hormones, and plasma proteins. In addition, the company offers antigens, such as human monoclonal IgE. Further, it provides lateral flow platform gRAD for the development of assays. The company sells its products through own sales team, distributors, and OEM partnerships. BioPorto A/S was founded in 2000 and is headquartered in Hellerup, Denmark.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.